BioCryst Pharmaceuticals | BCRX - Trade Creditors


BioCryst Pharmaceuticals reported $10.96M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
BioCryst Pharmaceuticals USD 10.96M 4.87M Mar/2026
Chugai Pharma JPY 107.52B 19.72B Mar/2026
Daiichi Sankyo JPY 568.5B 16.84B Dec/2025
DBV Technologies USD 39.82M 972K Sep/2025
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Gilead Sciences USD 645M 70M Mar/2026
GlaxoSmithKline GBP 14.34B 1.05B Mar/2026
Glaxosmithkline GBP 20.72B 346.14M Dec/2025
Incyte USD 228.62M 1.41B Mar/2026
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
Karyopharm Therapeutics USD 4M 1.39M Dec/2025
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novavax USD 16.1M 8.48M Mar/2026
PTC Therapeutics USD 25.48M 20M Mar/2026
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Roche Holding CHF 5.78B 1.27B Dec/2025
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
Vertex Pharmaceuticals USD 3.47B 40.6M Mar/2026